YERVOY® (ipilimumab) awarded prestigious Prix Galien USA 2012 for best biotechnology product

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE: BMY) today announced that YERVOY® (ipilimumab), a novel immunotherapy and the first medicine approved for unresectable or metastatic melanoma in more than a decade, received the Prix Galien USA 2012 Award for Best Biotechnology Product. The award, which is selected by a preeminent scientific committee that includes several Nobel Laureates, recognizes the technical, scientific and clinical research skills and achievements necessary to develop innovative medicines and devices and is considered the most prestigious prize in biopharmaceutical research and development.

"Immuno-oncology, or the science of harnessing the immune system to fight cancer, represents a new paradigm in the treatment of cancer and this requires a willingness to think differently about the discovery, development and commercialization of these novel agents," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer, and president, Research & Development, Bristol-Myers Squibb. "YERVOY is an important representation of the progress we have made in this innovative field and a great example of how the combined contributions of BioPharma, biotech and academia can make a difference in people's lives. We are proud that our work is being recognized by the Prix Galien USA Committee."

The mechanism of action of YERVOY's effect in patients with melanoma is indirect, possibly through T-cell-mediated anti-tumor immune responses. YERVOY is the only metastatic melanoma therapy proven in a Phase 3 study to deliver a durable long-term survival benefit at two years for 24% of previously-treated patients. In the study, median overall survival was 10 months (95% CI: 8.0-13.8) for YERVOY and 6 months (95% CI: 5.5-8.7) for the gp100 control arm.

Overall, the types of adverse events (AEs) attributed to YERVOY are generally mechanism (immune)- based. YERVOY can result in severe and fatal immune-related adverse reactions due to T-cell activation and proliferation. Adverse events associated with YERVOY were managed with protocol-specific guidelines, including the administration of systemic corticosteroids, dose interruption/discontinuation and/or other immunosuppressants.

YERVOY was also selected this year as a finalist for the Prix Galien prize in Germany under the category of specialized care. The award presentation will take place at the AXICA conference and convention center in Berlin on October 18, 2012.

The Prix Galien Awards were created to honor medical research and pharmacology for outstanding efforts to improve the human condition through approval of innovative treatments and medicines.

Immuno-Oncology at Bristol-Myers Squibb
Immuno-oncology, which focuses on the scientific potential of harnessing the unique properties of the immune system to fight cancer, is a prioritized area of research and development at Bristol-Myers Squibb. The Company is committed to leading advances in this important field of research and is exploring a variety of innovative compounds and immunotherapeutic approaches to help address significant unmet medical needs in a broad range of cancers.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...

Pfizer and BioNTech choose lead mRNA vaccine candi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a singl...